SMSNA Meeting

"This has been exciting from a physician-surgeon standpoint," says Helen L. Bernie, DO, MPH.

"I think what we definitively have is a device that's been around for over 50 years now that now we know significantly improves quality of life," says Andrew C. Peterson, MD, MPH.

"We found that the new TENACIO pump was able to complete tasks faster and more efficiently compared to the older MS pump," says Justin Lee, MD.

"I cannot wait to see what the SMSNA is going to have in store next year," says Helen L. Bernie, DO, MPH.

"The biggest complaint we saw, as far as negative outcomes, was loss of length," says Landon Trost, MD.

"The most significant rate of burnout has increased in female urologists," says Marah C. Hehemann, MD.

"What we found [with] 78 patients [was] that patient satisfaction was the same whether you place it in the prevesical space or the ectopic space," says Mohit Khera, MD, MBA, MPH.

"This study is significant because it really emphasizes the importance of early detection of both BPH and ED, because knowing that information can really preserve men's quality of life," says Olivia Paulsen.

"We found an increased association with AKI or acute kidney injury in the group receiving testosterone replacement therapy," said Evan Panken, MD.

None of the videos mentioned the long-term impact of exogenous testosterone on spermatogenesis.

Bajic summarizes his 2024 Sexual Medicine Society of North America Fall Scientific Meeting talk “Penile Prosthesis Biofilms: Friend or Foe?”

"What we found is that costs have really dramatically decreased year by year for all 3 medications," says Ellen Cahill, MD.

Almost all studies (93.5%) reported an improvement in validated patient-reported outcomes following treatment.

"I think patient preference is going to be the most important thing here," says Raevti Bole, MD.

SMSNA 2024 abstract data show shockwave therapies and platelet-rich plasma, either alone or in combination, may be promising treatments for ED.

68.8% of patients had at least a 30% improvement in ventral curvature from baseline.

“The take-home message…is it doesn't matter whether you put the reservoir in the ectopic location or the prevesical location. Patients tend to be satisfied in both locations,” said Mohit Khera, MD, MBA, MPH.

"We're also dealing with some cultural biases, and we have to be mindful [of] how do people like to discuss sexual medicine, and how does that impact our patient interactions?" says Denise Asafu-Adjei, MD, MPH.

The investigators reported a significantly greater prevalence of ED in men with BPH (P < .0001).

"Having a digital footprint is one of the most important things we can do as health care providers," says Amy Pearlman, MD.

"I think it's great, actually, that finally, we have more data on nutrition that we can recommend to our patients," says Stacy Loeb, MD, MSc, PhD (hon).

“Allowing these women to have a fulfilling life after cancer is one of the best things we can do as physicians,” says Talia A. Helman, MD.

"Looking at the survey results, we found that about 40% of men under the age of 40 are interested, at least, in supplementing their testosterone," says Justin Dubin, MD.

For the survey question “Do 5-ARIs reduce serum PSA?” 8 (9.4%) respondents said “no” and 25 (29.4%) said “not sure.”

Data from a Mayo Clinic study show, despite some reports of discomfort and dissatisfaction, a majority of patients receiving penile prosthesis are satisfied 1 year in.

"We see [urinary incontinence] in up to 62% of US women, and we know that in women with incontinence, about 25% report that it negatively impacts their sexual health," says Ramzy T. Burns, MD.

New research better defines the link between cardiovascular disease risk and prevalence of ED per serum ceramide levels.

Data from a new SMSNA 2024 abstract show an association between significantly high BMI and risk of azoospermia and oligospermia.

Following use of MED3000, the investigators reported significant improvements in all 5 SEP questions in both patients and partners over the course of the 12 weeks.

"The TRAVERSE trial is the largest randomized placebo-controlled trial ever published in men receiving testosterone vs placebo," says Mohit Khera, MD, MBA, MPH.